TrialSignal
Clinical trial intelligence report
Tolerability and Immunogenicity Study of FLUVAL P Monovalent Influenza Vaccine in Adults and Elderly Persons
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01010893
Status
COMPLETED
Phase
NA
Sponsor
Fluart Innovative Vaccine Ltd, Hungary
Executive brief
Investment-Ready Snapshot
The clinical trial assessed the tolerability and immunogenicity of the FLUVAL P monovalent influenza vaccine in adults and elderly individuals. Conducted by Fluart Innovative Vaccine Ltd, the study aimed to verify the vaccine's efficacy and safety profile, particularly in the context of pandemic influenza prevention.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01010893
Indication
Influenza
Modality
vaccine
Target
Influenza
Intervention
Vaccination with Fluval P and Fluval AB influenza vaccines, Vaccination with Fluval P monovalent influenza vaccine
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.